Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.

Chorea is an uncontrolled movement disorder caused by a hereditary condition called Huntington’s disease. A hereditary condition is a condition that is passed down from your parents.

These post-hoc analyses were conducted to assess the effect of INGREZZA on motor and cognitive burden among people with Huntington's disease (HD) chorea using the Huntington's Disease Health Index ...

Chorea is more common in people with adult-onset Huntington’s disease. Over time, symptoms may get worse, and movements may affect the legs and arms. Chorea-acanthocytosis ...

In the 12-week study, Unified Huntington's Disease Rating Scale Total Maximal Chorea (UHDRS-TMC) scores decreased by 4.6 points with valbenazine and by 1.4 points with placebo, a difference of 3.2 ...

Chorea is a characteristic type of involuntary movement in Huntington’s disease. This movement is often described as a smooth, writhing, squirmy, or twisting motion. It can affect any part of ...

Chorea in Huntington’s Disease. Huntington's disease is the best-known cause of chorea. It is a rare disease, which affects only about one in 10,000 to 20,000 people.

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

These same providers are expected to show a similar preference for Ingrezza in the treatment of HD chorea. The estimated number of Huntington's patients in the US ranges from 20,000 to 40,000 ...

Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to ...

Huntington’s disease is a rare genetic disorder affecting movement, memory, and mood. Here’s what we know—and what’s ahead.

- Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically Significant Clinical Global ...